Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1893-1903. doi: 10.1002/psp4.13211. Epub 2024 Sep 3.
Artemisinin-based combination therapy (ACT) is the first-line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate-amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin-piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed-effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one-compartment disposition model followed by a two-compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%-32.2% higher in pregnant women than that reported in non-pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three-compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non-pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non-pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy.
青蒿素为基础的联合疗法(ACT)是治疗无并发症疟疾的首选治疗方法。孕妇的药代动力学(PK)特性通常基于小型研究,需要在更大的孕妇人群中进行确认和验证。本研究旨在评估妊娠中期和晚期患有无并发症恶性疟原虫感染的孕妇体内阿莫地喹及其活性代谢物去乙基阿莫地喹和哌喹的 PK 特性。符合条件的孕妇接受青蒿琥酯-阿莫地喹(每日 200/540mg,n=771)或双氢青蒿素-哌喹(每日 40/960mg,n=755)治疗 3 天(NCT00852423)。采用非线性混合效应模型评估群体 PK 特性,并将孕龄和孕中期作为协变量进行评估。共纳入 1071 例阿莫地喹和 1087 例去乙基阿莫地喹以及 976 例哌喹的血药浓度进行群体 PK 分析。阿莫地喹浓度用一室分布模型和随后的去乙基阿莫地喹两室分布模型准确描述。阿莫地喹的相对生物利用度随孕龄增加(每周增加 1.25%)。与非孕妇相比,孕妇体内去乙基阿莫地喹的预测暴露量增加了 2.8%-32.2%,而第 7 天的浓度相当。哌喹浓度用三室分布模型充分描述。孕龄和孕中期对哌喹的 PK 无显著影响。哌喹的预测暴露量和第 7 天的浓度与非孕妇相似。总之,去乙基阿莫地喹和哌喹的暴露量与非孕妇相似。因此,妊娠中期和晚期的孕妇无需调整剂量。